Needham Reiterates Buy on Stoke Therapeutics, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Stoke Therapeutics (NASDAQ:STOK) and maintained a $14 price target.
February 16, 2024 | 10:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer reiterated a Buy rating on Stoke Therapeutics, maintaining a $14 price target.
The reiteration of a Buy rating and maintenance of a $14 price target by a reputable analyst suggests a positive outlook for Stoke Therapeutics, likely leading to increased investor confidence and potential upward movement in the stock's price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100